WINDTREE THERAPEUTICS INC /DE/ (WINT)
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases. Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension. The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure. It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016. It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases.
Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension.
The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure.
It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016.
It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US| Insider | Title | Type | Shares | Value | Date |
|---|---|---|---|---|---|
 Fraser Craig | President and CEO | Purchase | 5.4K | $4.9K | Oct 8, 2024 |
| Name | Shares | % | Source |
|---|---|---|---|
 Fraser Craig President and CEO, Director | 173 | 0.0% | FORM 4 |
Insiders
- Fraser CraigPresident and CEO
Windtree Therapeutics, Inc. is a clinical-stage biopharmaceutical firm primarily dedicated to developing therapies for acute cardiovascular ailments, and secondarily for acute pulmonary diseases.
Its prominent therapeutic programs include istaroxime, undergoing Phase IIb clinical trials for acute decompensated heart failure and Phase IIa for early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant in Phase IIb for respiratory distress syndrome in preterm infants; Lyophilized KL4 surfactant, in Phase IIa trials for lung injury stemming from COVID-19; and Rostafuroxin, in Phase IIb for genetically associated hypertension.
The company maintains collaborations, including one with Universita degli Studi di Milano-Bicocca for the discovery and advancement of novel SERCA2a compounds targeting chronic and acute human heart failure.
It also holds a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and commercialization of a portfolio of potential KL4 surfactant products, and a collaboration with Battelle Memorial Institute to further develop its ADS for its Phase III program. Established in 1992 as Discovery Laboratories, Inc., the company rebranded as Windtree Therapeutics, Inc. in April 2016.
It is headquartered in Warrington, Pennsylvania, and operates as a subsidiary of Lee's Pharmaceutical Holdings Limited.
No 13F filer reports a position yet. 13F reports are quarterly and are filed up to 45 days after the quarter ends.
US30d Avg
19.38K
60d Avg
13.92K
90d Avg
40.55K